Despite being the most common vaginal condition,1 BV symptoms are often mistaken for a yeast infection2 JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a ...
SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) approved ...
LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin ...
December 1, 2006 — The US Food and Drug Administration (FDA) has approved clindamycin phosphate/tretinoin 1.2%/0.025% gel for the once-daily topical treatment of acne vulgaris in patients aged 12 ...
FT. WORTH, Texas--(BUSINESS WIRE)--One of the most widely prescribed drugs for acne vulgaris is benzoyl peroxide (BPO). However, at concentrations of 5-10%, BPO has the potential for skin irritation ...
Clindamycin phosphate 1.2%; tretinoin 0.025%; gel. Ziana is a topical gel for acne that combines clindamycin and tretinoin. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein ...
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results